Tempest Therapeutics, Inc. (TPST) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US87978U2078
Tempest Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -26.58 m USD |
| EBIT | -26.06 m USD |
| Net income | -26.26 m USD |
| Diluted EPS – continuing operations | -6.33 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
More stocks
- iQSTEL Inc (IQST)
- MultiSensor AI Holdings, Inc. (MSAI)
- Monroe Federal Bancorp, Inc. (MFBI)
- AMERICAS CARMART INC (CRMT)
- System1, Inc. (SST)
- GT Biopharma, Inc. (GTBP)
- Bodhi Tree Biotechnology Inc (BDTB)
- CFN Enterprises Inc. (CNFN)
- XERIANT, INC. (XERI)
- Bridgeline Digital, Inc. (BLIN)
- Curanex Pharmaceuticals Inc (CURX)
- BTC Digital Ltd. (BTCT)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.